Telix Pharmaceuticals Ltd — AGM Information 2022

May 4, 2022

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [146 x 81] intentionally omitted <==

ASX RELEASE

Telix Annual General Meeting Change to proposed amendments to the Telix Constitution

Melbourne (Australia) – 5 May 2022 . Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) refers to resolution 9 of the Notice of Meeting for the 2022 Annual General Meeting ("Meeting"), to be held on Wednesday, 18 May 2022, which proposes a number of amendments to the Telix Constitution ("Constitution").

One of the proposed amendments is the insertion of new rule 7.6 (Virtual meetings) in the Constitution, which would allow Telix to hold meetings of shareholders using virtual meeting technology only. This amendment is aimed at responding to provisions of the recently enacted Corporations Amendment (Meetings and Documents) Act 2022 (Cth), which provided for permanent changes in relation to (among other matters) the holding of virtual shareholder meetings.

Given the importance of this new rule, the Company has considered it prudent to clarify the circumstances in which the Board may consider it appropriate to hold a virtual only meeting - namely, where it is reasonable to do so having regard to health and safety concerns or any government imposed restrictions or lockdowns.

Accordingly, Telix has proposed a clarifying change to rule 7.6 in the Constitution, which is shown in mark-up in the attached Annexure for ease of reference.

All other proposed amendments to the Constitution will remain as previously contemplated and be put to shareholders for approval at the Meeting.

A revised copy of the amended Constitution is available on the Company's website: - https://telixpharma.com/investors/#corporate governance

The change to the proposed amendments to the Constitution described above will not affect the validity of proxy forms, or any proxy votes, already submitted in respect of resolution 9 or the remaining items of business to be considered at the Meeting. Shareholders can withdraw or re-lodge any proxies already lodged with the Share Registry, if they wish to do so.

This announcement has been authorised for release by the Board.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix’s lead product, Illuccix[®] (kit for preparation of gallium-68 ([68] Ga) gozetotide (also known as[68] Ga PSMA11) injection) for prostate cancer imaging, has been approved by the U.S. Food and Drug

Page 1

Administration(FDA),[1] and by the Australian Therapeutic Goods Administration (TGA).[2] Telix is also progressing marketing authorisation applications for this investigational candidate in Europe[3] and Canada.[4]

Telix Investor Relations

Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: kyahn.williamson@telixpharma.com

Annexure

7.6 Virtual meetings

• (a) The Board may determine, where it is reasonable to do so having regard to health and safety concerns or any government imposed restrictions or lockdowns, that there be no physical place of a general meeting and that the general meeting may be conducted virtually such that each participant in the meeting is linked by an instantaneous audio-visual communication device which, by itself or in conjunction with other arrangements:

• (i) gives the members entitled to attend the meeting, as a whole, a reasonable opportunity to participate in proceedings, including a reasonable opportunity to exercise a right to speak and ask questions (either orally or in writing, at the member's election);

• (ii) enables the chairperson to be aware of proceedings of the meeting;

• (iii) enables the members attending the meeting to vote on a show of hands or on a poll; and

• (iv) enables all documents required or permitted to be tabled at the meeting to be made accessible to the members attending the meeting (either before or during the meeting).

in which case a member present via the audio-visual communication device is taken to be present at the general meeting and entitled to exercise all rights as if he or she was present at the general meeting.

• (b) A meeting that is held in accordance with rule 7.6(a) must be held at a time that is reasonable at the registered office of the company.

• (c) If, before or during the general meeting, any technical difficulty occurs where one or more of the matters set out in rule 7.6(a) is not satisfied, the chairperson may:

• (i) adjourn the meeting until the difficulty is remedied; or

• (ii) continue to hold the meeting in each place which is linked under rule 7.6(a) and transact business, and no member may object to the meeting being held or continuing.

• (d) Nothing in this rule 7.6 or in rule 7.9 is to be taken to limit the powers conferred on the chairperson by law.

1 ASX disclosure 20 December 2021.

2 ASX disclosure 2 November 2021.

3 ASX disclosure 10 December 2021.

4 ASX disclosure 16 December 2020.

Page 2

Legal Notices

This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.

The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

Page 3